EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treatment with programmed-death-1 inhibitors for non-melanoma skin cancer among immunocompromised patients with subgroup analysis of solid organ transplant patients

Eyal Yosefof iD, Nofar Edri, Idan Ben-Nachum, Dan Yaniv, Aviram Mizrachi, Nethanel Asher, Naomi Ben-Dor, Avital Ben-Artzi, Itamar Averbuch, Noga Kurman

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Eyal Yosefof und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva 4941492, Israel. Hauptthemen laut MEDLINE: Skin Neoplasms, Organ Transplantation, Immunocompromised Host, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Programmed-cell death protein 1 (PD-1) inhibitors have emerged as a standard of care treatment among advanced-stage or metastatic cutaneous squamous cell carcinoma (cSCC). Immune-compromised patients and particularly solid organ transplant recipients (SOTRs) are considered at high risk for cSCC. When treated with PD-1 inhibitors, the possibility of organ rejection, autoimmune flare, or insufficient response to treatment is feared. As these patients were excluded from past prospective clinical trials, we aim to describe our institute’s experience regarding these patients.

Methods

A retrospective analysis was conducted on cSCC patients treated with PD-1 inhibitors. Comparisons were made between immune-compromised and immune-competent groups, with a subgroup analysis of SOTR.

Results

The study cohort comprised of 133 patients, including 97.8% receiving Cemiplimab with a mean age of 77.2 ± 11.7 years. Immune-compromised patients constituted 26.9% (n = 35) of the cohort, including 10 SOTR (all kidney transplant recipients). Objective response rates (ORRs) and disease control rates (DCR) were comparable between immunocompetent and immunosuppressed patients receiving Cemiplimab (ORR: 76.8% vs 62.9%, P = .12; DCR: 81.1% vs 68.6%, P = .13). SOTR demonstrated an 80% ORR and DCR. Progression-free survival was comparable across all groups. Toxicity rates were similar between immunosuppressed and immunocompetent subgroups (68.6% vs 62.1%, P = .5). Two OTRs (20%) experienced acute graft rejection.

Conclusions

PD-1 inhibitors demonstrate efficacy and safety in immunosuppressed cSCC patients. While effective in SOTR, treatment requires multidisciplinary management due to the potential risk of organ rejection. These findings provide valuable insights into this understudied population and support the use of PD-1 inhibitors in immunosuppressed patients with advanced cSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsOrgan TransplantationImmunocompromised HostImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorCarcinoma, Squamous CellHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

cutaneous squamous cell carcinomaimmune checkpoint inhibitorsimmunocompromised patientskidney transplant patientsorgan transplant patients

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Otorhinolaryngology and Head and Neck Surgery, Rabin Medical Center-Beilinson Hospital, Petach Tikva 4941492, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Davidoff Cancer Center, Rabin Medical Center, Petah Tikva 4941492, Israel.
  • Department of Otolaryngology - Head and Neck Surgery, Weill Cornell Medical College, Cornell University, New York, NY 10065, United States.
  • Department of Nephrology and Hypertension, Rabin Medical Center, Petah Tikva 4941492, Israel.
  • Department of Nuclear Medicine and Department of Imaging, Rabin Medical Center, Petah Tikva 4941492, Israel.

ORCID-Profile: Eyal Yosefof

Zitieren

APA

Yosefof, E., Edri, N., Ben-Nachum, I., Yaniv, D., Mizrachi, A., Asher, N., Ben-Dor, N., Ben-Artzi, A., Averbuch, I., & Kurman, N. (2025). Treatment with programmed-death-1 inhibitors for non-melanoma skin cancer among immunocompromised patients with subgroup analysis of solid organ transplant patients. The Oncologist. https://doi.org/10.1093/oncolo/oyaf022

Vancouver

Yosefof E, Edri N, Ben-Nachum I, Yaniv D, Mizrachi A, Asher N, et al. Treatment with programmed-death-1 inhibitors for non-melanoma skin cancer among immunocompromised patients with subgroup analysis of solid organ transplant patients. The Oncologist. 2025. doi:10.1093/oncolo/oyaf022

BibTeX
@article{Yosefof2025,
  author = {Yosefof, Eyal and Edri, Nofar and Ben-Nachum, Idan and Yaniv, Dan and Mizrachi, Aviram and Asher, Nethanel and Ben-Dor, Naomi and Ben-Artzi, Avital and Averbuch, Itamar and Kurman, Noga},
  title = {Treatment with programmed-death-1 inhibitors for non-melanoma skin cancer among immunocompromised patients with subgroup analysis of solid organ transplant patients},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf022}
}
Kostenlos starten →